Skip to main content

Table 3 Selection of phase II studies of gemcitabine in advanced biliary tract cancer.

From: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

Study Number of assessable patients Response SD PFS (months) OS (months)
Metzger et al (16) 13 1 (8%) 11 (85%) 7 16
Verderame et al (17) 4 1 (25%) 3 (75%) 11 NR
Gebbia et al (18) 18 4 (22%) 5 (28%) 3 8
Penz et al (19) 32 7 (22%) 14 (44%) 6 12
Lin et al (20) 24 3 (13%) 8 (33%) 3 7
Eng (21) 14 0 (0%) 2 (13%) 2 5
Tsavaris et al (22) 30 9 (30%) 11 (37%) 7 14
Park et al (23) 23 6 (26%) 8 (35%) 8 13
  1. Abbreviations: NR, not reported; OS, overall survival; PFS, progression-free survival; SD, stable disease.